Professor Mark Wilcox

Professor Mark Wilcox

Professor of Medical Microbiology

0113 392 6818

Summary: Professor of Medical Microbiology

Location: Microbiology, Old Medical School, Leeds General Infirmary

Teaching Commitments: Lectures to undergraduate students in Medicine, Dentistry, and Science (Microbiology).


Professor Mark Wilcox is a Consultant Microbiologist, Head of Research and Development in Microbiology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds (Leeds Institute of Molecular Medicine), and is the Lead on Clostridium difficile for the Public Health England (PHE).  Medical Advisor to National Infection PRevention & Control Lead (NHS Improvement), England.

He has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years) and Clinical Director of Pathology (6 years) at LTHT and Head of Microbiology (15 years)

Professor Wilcox is Chair of PHE's Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), Deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and is a member of the PHE's Programme Board on Healthcare Associated Infection & Antimicrobial Resistance.  He is a member of the Medical Research Concil's Infections and Immunity Board, and the Scientific Adivsory Board of the EU Innovative Medicines Initiative (IMI) COMBACTE-NET consortium.  From 2017, he has been seconded one day per week to NHS Improvement to support the delivery of the new national target to reduce healthcare associated Gram-negative blood stream infections in England.

He is an advisor to the Department of Health in England on healthcare associated infections (HCAIs), the UK EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust and CARB-X panel on novel antimicrobials, and the European Centre for Disease Control.  He is a member of UK, European and US working groups on C. difficile infection, and is on the Editorial Boards of Lancet Gastroenterology & Hepatology, Journal of Hospital infection and Infectious Diseases in Clinical Practice.  He has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents, 1998-2016.

Professor Wilcox heads the Healthcare Associated Infection research team at the University of Leeds (, comprising ~30 doctors, scientists and nurses; projects include multiple aspects of Clostridium difficile infection, diagnostics, antibiotic resistance and the gut microbiome, staphylococcal infection, and the clinical development of new antimicrobial agents.  He has a track record of translational research, including providing the basis of clinical advice to the NHS, and influencing infection management policies internationally.  From 2017, he co-leads the EU IMI COMBACT-CDI consortium research project.  He has been the Principal/UK Investigator for 14 clinical trials of new anti-infective drugs, 1999-2016, has carried out multiple NIHR portfolio studies on healthcare associated infection topics and is currently supplying central laboratory services for several clinical trials of antimicrobial agents.  He has authored more than >430 papers and published a number of books and chapters.  He is co-editor of Antimicrobial Chemotherapy (5th/6th/7th Eds, 2007/12/15).